


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) ~~Use of~~ A method of producing a therapeutic agent for the treatment of myeloproliferative diseases and for bronchodilation in mammals comprising administering to a patient in need thereof an effective amount of a 2-amino-2H-quinazoline derivatives derivative of the general chemical formula I



wherein R1 is an alkyl group with 1-5 carbon atoms and R2, R3, R4 and R5, independently of one another, each indicate a chlorine or hydrogen atom, as well as their pharmaceutically compatible salts, ~~for producing therapeutic agents for the treatment of myeloproliferative diseases and for bronchodilation in mammals.~~

2. (Currently amended) The ~~use~~ method according to claim 1, further characterized in that at least two residues of R2, R3, R4 and R5 each indicate chlorine atoms.


3. (Currently amended) The ~~use~~ method according to claim 1, further characterized in that R1 stands for methyl or ethyl, R2 and R3 are each hydrogens, and R4 and R5 are

each chlorine atoms.

4. (Currently amended) The ~~use~~ method according to claim 1, further characterized in that the pharmaceutically compatible salts are selected from the group comprising the hydrochloride, hydrobromide, sulfate, fumarate, maleate, lactate and succinate.


5. (Currently amended) The ~~use~~ method according to claim 1, further characterized in that the 2-amino-2H-quinazoline derivatives are selected from the group comprising methyl-(2-amino-5,6-dichloro-3,4-dihydro-2H-quinazolin-3-yl) acetate hydrochloride hemihydrate, methyl-(2-amino-5,6-dichloro-3,4-dihydro-2H-quinazolin-3-yl) acetate hydrobromide hemihydrate, ethyl-(2-amino-5,6-dichloro-3,4-dihydro-2H-quinazolin-3-yl) acetate hydrochloride hemihydrate, and ethyl-(2-amino-5,6-dichloro-3,4-dihydro-2H-quinazolin-3-yl) acetate hydrobromide hemihydrate.

6. (Currently amended) ~~Use~~ A method for the treatment of myeloproliferative diseases and for bronchodilation in mammals comprising administering to a patient in need thereof an effective amount of 2-amino-2H-quinazoline derivatives of the general chemical formula I



wherein R1 indicates an alkyl group with 1-5 carbon atoms and R2, R3, R4 and R5, independently of one another, each indicate a chlorine or hydrogen atom, and their pharmaceutically compatible salts, ~~for the treatment of myeloproliferative diseases and for bronchodilation in mammals.~~

7. (Currently amended) Use A method for the treatment of myeloproliferative diseases and for bronchodilation in mammals comprising administering to a patient in need thereof an effective amount of a pharmaceutical preparation containing at least one ~~agent,~~ selected from the group comprising 2-amino-2H-quinazoline derivatives derivative of the general chemical formula I




wherein R1 is an alkyl group with 1-5 carbon atoms and R2, R3, R4 and R5, independently of one another, each indicate a chlorine or hydrogen atom, and their pharmaceutically compatible salts, and at least one pharmaceutically compatible

adjuvant, ~~for the treatment of myeloproliferative diseases and for bronchodilation in mammals.~~


8. (Currently amended) ~~The use of the pharmaceutical preparation method~~ according to claim 7, further characterized in that at least one of the pharmaceutically compatible adjuvants reacts basically in aqueous medium.

9. (New) A method of producing a pharmaceutical preparation comprising combining a 2-amino-2H-quinazoline derivative of the general chemical formula I




wherein R1 is an alkyl group with 1-5 carbon atoms and R2, R3, R4 and R5, independently of one another, each indicate a chlorine or hydrogen atom, as well as their pharmaceutically compatible salts, with at least one pharmaceutically compatible adjuvant.

10. (New) A method of producing anagrelide comprising administering to a mammal a 2-amino-2H-quinazoline derivative of the general chemical formula I



wherein R1 is an alkyl group with 1-5 carbon atoms and R2, R3, R4 and R5, independently of one another, each indicate a chlorine or hydrogen atom, as well as their pharmaceutically compatible salts.

11. (New) A method for the treatment of blood platelet aggregation in mammals comprising administering to a patient in need thereof an effective amount of 2-amino-2H-quinazoline derivatives of the general chemical formula I



wherein R1 indicates an alkyl group with 1-5 carbon atoms and R2, R3, R4 and R5, independently of one another, each indicate a chlorine or hydrogen atom, and their pharmaceutically compatible salts.